CONTINUE FROM PREVIOUS UPDATE

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.

Additionally, the treatment demonstrated comprehensive benefits, achieving statistical significance across six key secondary measures: improved sleep quality, reduced fatigue, enhanced physical function, better overall symptoms, and increased patient satisfaction.

The medication, which was generally well-tolerated with no new safety concerns, represents a potential breakthrough for fibromyalgia patients. Tonix submitted a New Drug Application (NDA) to the FDA in October 2024, with an anticipated decision in 2025. If approved, this would mark the first new fibromyalgia treatment in over 15 years, offering a novel approach by addressing sleep disturbances.

Dr. Lederman also highlighted other recent milestones, including Fast Track designation from the FDA and a $34 million Department of Defense contract for antiviral research. With $28 million in cash reserves reported at the close of Q3, Tonix Pharmaceuticals is well-positioned for continued innovation and growth.